247 research outputs found
The Idea Of Sacrifices as Related to the Idea of Cleansing in the Book of Leviticus and the Epistle to the Hebrews
Attitudes and Family Farm Business Performance
This study aimed to identify the top performing and the bottom performing family farm businesses based upon business performance, and then compare and contrast the perceptions and attitudes towards acquiring management skills and attributes that lead to improved business performance. Using extensive interviews data were obtained from 200 family farm businesses from New South Wales and Victoria covering a range of enterprises. The key findings were, firstly, that for all farmers the maintaining of a stable family relationship was of paramount importance in the running of the farm business. Secondly, that the Top 20% of farmers had high levels of self-efficacy and thus possessed the capability and the competence to perform tasks successfully. High performers also were more committed to the creation of long-term wealth and viewed business skills as a higher priority for training. Low performers were more highly committed to the farm's environmental health, placed a greater emphasis on production and sustainability for training and were more likely to give a lower priority to business issues. Both groups agreed that formal training that involved practical farmers with education skills providing them with tailor-made modules were best suited to their personal learning needs. The consistently high priority of family and business issues suggests that the opportunity exists to integrate the training of attitudes and skills with family, sustainable business practices and community issues. The study was funded by the Rural Industries Research and Development Corporation.Farm Management,
Recommended from our members
The impact of business accelerators and incubators in the UK
This report explores how incubators and accelerators impact the startups they support, and which types of support drive this impact. It also examines how incubators and accelerators affect the wider business ecosystem.
The report:
- examines the objectives of UK accelerators and incubators, and the barriers to reaching these objectives
- determines which types of support offered by incubators and accelerators (for example provision of workspace, mentoring, funding or training) add the most value to participating startups
- presents a ātheory of changeā explaining how these types of support make their impact
- investigates how Local Enterprise partnerships and Growth Hubs interact with or support accelerators and incubators in their region, and how this interaction helps both parties achieve their objective
Vitamin D and Cardiovascular Disease
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90252/1/phco.29.6.691.pd
Ursinus College Alumni Journal, Spring 1969
Mark your calendar ā¢ Mailer: Anatomizer of the moral malaise ā¢ From the President ā¢ The dimensions of history ā¢ Centennial celebration report ā¢ Ursinus names new alumni director ā¢ Revised Alumni Association constitution ā¢ The end of an era ā¢ Financial development report: steady progress ā¢ A bride for the first time ā¢ Candidates for office ā¢ Girls\u27 field hockey review ā¢ Ursinus Women\u27s Club: A record of achievement ā¢ Campus clippings: 100 years ago; News media report; Coach and athlete ā¢ Class notes ā¢ In memoriam ā¢ Weddings ā¢ Birthshttps://digitalcommons.ursinus.edu/alumnijournal/1094/thumbnail.jp
OR30-1 Safety and Efficacy of Recombinant Human Parathyroid Hormone 1-84 for the Treatment of Adults with Chronic Hypoparathyroidism: Six-Year Results of the RACE Study
RACE is an open-label study that assessed the long-term safety and efficacy of recombinant human parathyroid hormone 1-84 (rhPTH[1-84]) for the treatment of hypoparathyroidism in adults (ClinicalTrials.gov identifier NCT01297309). Patients initially received 25 or 50 Āµg/day of rhPTH(1-84) subcutaneously, once daily, with stepwise dose adjustments of 25 Āµg (up or down) to a maximum of 100 Āµg/day. rhPTH(1-84) could be titrated and oral calcium (Ca) and calcitriol doses adjusted at any time during the study to maintain albumin-corrected serum Ca levels in the target range of 8.0-9.0 mg/dL. A composite efficacy endpoint was the proportion of patients who achieved at least a 50% reduction from baseline (BL) in oral Ca dose (or Ca ā¤500 mg/day) and at least a 50% reduction from BL in calcitriol dose (or calcitriol ā¤0.25 Āµg/day), while normalizing or maintaining albumin-corrected serum Ca compared with BL value and not exceeding the upper limit of normal for the central laboratory. Here, we present 6-year safety and efficacy data with descriptive summary statistics (mean Ā± SD). The study cohort consisted of 49 patients enrolled at 12 US centers (mean age, 48.1Ā±9.78 years; 81.6% female); data from 34 patients (69.4%) who completed 72 months (M72) of treatment with rhPTH(1-84) as of July 17, 2018 are presented here. Oral Ca and calcitriol doses were reduced by 40.4% and 72.2% at M72, respectively, and albumin-corrected serum Ca levels were maintained within the target range (BL, 8.4Ā±0.70 mg/dL; M72, 8.4Ā±0.68 mg/dL). At M72, 22 of 34 patients (64.7%) achieved the composite efficacy endpoint. Urinary Ca excretion declined from above-normal at BL to within the normal range (BL, 356.7Ā±200.37 mg/24 h; M72, 213.2Ā±128.82 mg/24 h). Mean serum creatinine levels remained stable (BL, 1.0Ā±0.21 mg/dL; M72, 0.9Ā±0.21 mg/dL), as did estimated glomerular filtration rate (eGFR; BL, 77.7Ā±17.67 mL/min/1.73 m2; M72, 79.4Ā±18.39 mL/min/1.73 m2). Serum phosphorus levels declined from above-normal at BL to within normal range (BL, 4.8Ā±0.58 mg/dL; M72, 4.0Ā±0.62 mg/dL); calcium-phosphorus product levels also declined (BL, 42.1Ā±6.35 mg2/dL2; M72, 33.7Ā±5.01 mg2/dL2). Treatment-emergent adverse events and treatment-emergent serious adverse events were reported in 98.0% and 26.5% of patients, respectively; no new safety concerns were identified. Continuous use of rhPTH(1-84) over 6 years resulted in a favorable safety profile, was effective, and improved key measurements of mineral homeostasis, notably normalization of urinary calcium. Disclosures: All of the authors disclose a relationship with Shire: advisory board member, JPB, MAL, MM, DMS, TJV; consultant, JPB, BLC, MAL, MM, DMS, TJV; grant recipient, JPB, DD, MM, MP, DMS, MLW; employee, H-ML, NS; research investigator, JPB, HB, JR, DMS, TJV, MLW, NBW; speaker, JPB, HB, MLW, NBW. Funding: Shir
Ten Yearsā Experience with Alendronate for Osteoporosis in Postmenopausal Women
Background
Antiresorptive agents are widely used to treat osteoporosis. We report the results of a multinational randomized, double-blind study, in which postmenopausal women with osteoporosis were treated with alendronate for up to 10 years.
Methods
The initial three-year phase of the study compared three daily doses of alendronate with placebo. Women in the original placebo group received alendronate in years 4 and 5 and then were discharged. Women in the original active-treatment groups continued to receive alendronate during the initial extension (years 4 and 5). In two further extensions (years 6 and 7, and 8 through 10), women who had received 5 mg or 10 mg of alendronate daily continued on the same treatment. Women in the discontinuation group received 20 mg of alendronate daily for two years and 5 mg daily in years 3, 4, and 5, followed by five years of placebo. Randomized group assignments and blinding were maintained throughout the 10 years. We report results for the 247 women who participated in all four phases of the study.
Results
Treatment with 10 mg of alendronate daily for 10 years produced mean increases in bone mineral density of 13.7 percent at the lumbar spine (95 percent confidence interval, 12.0 to 15.5 percent), 10.3 percent at the trochanter (95 percent confidence interval, 8.1 to 12.4 percent), 5.4 percent at the femoral neck (95 percent confidence interval, 3.5 to 7.4 percent), and 6.7 percent at the total proximal femur (95 percent confidence interval, 4.4 to 9.1 percent) as compared with base-line values; smaller gains occurred in the group given 5 mg daily. The discontinuation of alendronate resulted in a gradual loss of effect, as measured by bone density and biochemical markers of bone remodeling. Safety data, including fractures and stature, did not suggest that prolonged treatment resulted in any loss of benefit.
Conclusions
The therapeutic effects of alendronate were sustained, and the drug was well tolerated over a 10-year period. The discontinuation of alendronate resulted in the gradual loss of its effects
Ursinus College Alumni Journal, November 1968
Ursinus College calendar ā¢ Politics 1968: That was the year that was ā¢ From the President ā¢ All-Ursinus anniversary drive: A report from the National Chairman ā¢ Stained glass on campus ā¢ An end of Pax Americana ā¢ Freeland Hall: A birthplace revisited ā¢ Episodes in the life of Freeland Hall ā¢ Homecoming 1968 ā¢ Centennial: The liberal arts in higher learning ā¢ Sports scene: Miss Snell honored; Harriers keep winning; Mills keeps kicking ā¢ Ursinus honors four at Founders\u27 Day ā¢ Church appeal gains momentum ā¢ Class of \u2772: A pictorial essay ā¢ Campus clippings: Alumni award planned; Television stars; Beatle buff on campus; Subscribe to the Weekly ā¢ Class notes ā¢ Weddings ā¢ Births ā¢ In memoriamhttps://digitalcommons.ursinus.edu/alumnijournal/1093/thumbnail.jp
Odanacatib for the treatment of postmenopausal osteoporosis: Development history and design and participant characteristics of LoFT, the Long-term odanacatib Fracture Trial
Summary: Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and increases bone mineral density, with only a transient decrease in bone formation. We describe the background, design and participant characteristics for the phase 3 registration trial. Introduction: Odanacatib (ODN) is a selective cathepsin K inhibitor being evaluated for the treatment of osteoporosis. In a phase 2 trial, ODN 50 mg once weekly reduced bone resorption while preserving bone formation and progressively increased BMD over 5 years. We describe the phase III Long-Term ODN Fracture Trial (LOFT), an event-driven, randomized, blinded placebo-controlled trial, with preplanned interim analyses to permit early termination if significant fracture risk reduction was demonstrated. An extension was planned, with participants remaining on their randomized treatment for up to 5 years, then transitioning to open-label ODN. Methods: The three primary outcomes were radiologically determined vertebral, hip, and clinical non-vertebral fractures. Secondary end points included clinical vertebral fractures, BMD, bone turnover markers, and safety and tolerability, including bone histology. Participants were women, 65 years or older, with a BMD T-score ā¤ā2.5 at the total hip (TH) or femoral neck (FN) or with a prior radiographic vertebral fracture and a T-score ā¤ā1.5 at the TH or FN. They were randomized to ODN or placebo tablets. All received weekly vitamin D3 (5600 international units (IU)) and daily calcium supplements as needed to ensure a daily intake of approximately 1200 mg. Results: Altogether, 16,713 participants were randomized at 387 centers. After a planned interim analysis, an independent data monitoring committee recommended that the study be stopped early due to robust efficacy and a favorable benefit/risk profile. Following the base study closeout, 8256 participants entered the study extension. Conclusions: This report details the background and study design of this fracture end point trial and describes the baseline characteristics of its participants
Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism
CONTEXT:
Conventional hypoparathyroidism treatment with oral calcium and active vitamin D is aimed at correcting hypocalcemia but does not address other physiologic defects caused by PTH deficiency.
OBJECTIVE:
To evaluate long-term safety and tolerability of recombinant human PTH (1-84) [rhPTH(1-84)].
DESIGN:
Open-label extension study; 5-year interim analysis.
SETTING:
12 US centers.
PATIENTS:
Adults (N = 49) with chronic hypoparathyroidism.
INTERVENTION(S):
rhPTH(1-84) 25 or 50 Āµg/d initially, with 25-Āµg adjustments permitted to a 100 Āµg/d maximum.
MAIN OUTCOME MEASURE(S):
Safety parameters; composite efficacy outcome was the proportion of patients with ā„50% reduction in oral calcium (or ā¤500 mg/d) and calcitriol (or ā¤0.25 Āµg/d) doses, and albumin-corrected serum calcium normalized or maintained compared with baseline, not exceeding upper limit of normal.
RESULTS:
Forty patients completed 60 months of treatment. Mean albumin-corrected serum calcium levels remained between 8.2 and 8.7 mg/dL. Between baseline and month 60, levels Ā± SD of urinary calcium, serum phosphorus, and calcium-phosphorus product decreased by 101.2 Ā± 236.24 mg/24 hours, 1.0 Ā± 0.78 mg/dL, and 8.5 Ā± 8.29 mg2/dL2, respectively. Serum creatinine level and estimated glomerular filtration rate were unchanged. Treatment-emergent adverse events (AEs) were reported in 48 patients (98.0%; hypocalcemia, 36.7%; muscle spasms, 32.7%; paresthesia, 30.6%; sinusitis, 30.6%; nausea, 30.6%) and serious AEs in 13 (26.5%). At month 60, 28 patients (70.0%) achieved the composite efficacy outcome. Bone turnover markers increased, peaked at ā¼12 months, and then declined to values that remained above baseline.
CONCLUSION:
Treatment with rhPTH(1-84) for 5 years demonstrated a safety profile consistent with previous studies and improved key biochemical parameters
- ā¦